Schizophrenia: Glutathione deficit as a new vulnerability factor for disconnectivity syndrome

Schweizer Archiv fur Neurologie und Psychiatrie

Volumn 155, Issue 8, 2004, Pages 375-385

  Do, Kim Q ^a,b,c   Bovet, P ^b   Cuenod, M ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Disconnectivity; Dopamine; Glutathione; NMDA; Oxidative stress; Schizophrenia

Indexed keywords

DOPAMINE RECEPTOR; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE SYNTHASE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; REACTIVE OXYGEN METABOLITE;

ARTICLE; CEREBROSPINAL FLUID; COGNITION; DENDRITIC SPINE; DISEASE SEVERITY; DOPAMINE METABOLISM; FIBROBLAST; HUMAN; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PERSONALITY; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 13544272799     PISSN: 02587661     EISSN: None     Source Type: Journal    
DOI: 10.4414/sanp.2004.01534     Document Type: Article

References (103)

1. Gross G, Huber G, Klosterkötter J, Linz M. BSABS Bonner Skala für die Beurteilung von Basissymptomen - Bonn Scale for the Assessment of Basic Symptoms. Berlin: Springer; 1987.
2. Chapman LJ, Chapman JP. The search for symptoms predictive of schizophrenia. Schizophr Bull 1987;13:497-503
3. Andreasen NC. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 2000;31:106-12.
4. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000;28:325-34.
5. Gottesman II, Shields J. Schizophrenia: the Epigentic Puzzle. Cambridge: Cambridge University Press; 2001.
6. Risch N. Mapping genes for psychiatric disorders. In: Gershon ES, Cloninger CR, editors. Genetic Approaches to Mental Disorders. Washington DC: American Psychiatric Press, Inc.; 1994. p. 47-61.
7. Barr CL, Kennedy JL, Pakstis AJ, Wetterberg L, Sjögren B, Bierut L, et al. Progress in a genome scan for linkage in schizophrenia in a large Swedish kindred. Am J Med Genet 1994;54:51-8.
8. Coon H, Jensen S, Holik J, Hoff M, Myles-Worsley M, Reimherr F, et al. Genomic scan for genes predisposing to schizophrenia. Am J Med Genet 1994;54:59-71.
9. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G, et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998;20:70-3.
10. Brzustowicz LM, Honer WG, Chow EW, Little D, Hogan J, Hodgkinson K, et al. Linkage of familial schizophrenia to chromosome 13q32. Am J Hum Genet 1999;65:1096-103.
11. Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 2000;288:678-82.
12. Pulver AE. Search for schizophrenia susceptibility genes. Biol Psychiatry 2000;47:221-30.
13. Faraone SV, Taylor L, Tsuang MT. The molecular genetics of schizophrenia: an emerging consensus. Expert Rev Mol Med 2002;2002:1-13.
14. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003;73:34-48.
15. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004;254:4-8.
16. Cannon TD, Rosso IM, Hollister JM, Bearden CE, Sanchez LE, Hadley T. A prospective cohort study of genetic and perinatal influences in the etiology of schizophrenia. Schizophr Bull 2000;26:351-66.
17. Rosso IM, Cannon TD, Huttunen T, Huttunen MO, Lönnqvist J, Gasperoni TL. Obstetric risk factors for early-onset schizophrenia in a Finnish birth cohort. Am J Psychiatry 2000;157:801-7.
18. Marcelis M, Van Os J, Sham P, Jones P, Gilvarry C, Cannon M, et al. Obstetric complications and familial morbid risk of psychiatric disorders. Am J Med Genet 1998;81:29-36.
19. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc 1973;32:200-5.
20. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86.
21. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-86.
22. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett 1980;20:379-82.
23. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease [review]. Trends Neurosci 1990;13:272-6.
24. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A "Glutamatergic hypothesis" of schizophrenia. Clin Neuropharmacol 1989;12:1-13.
25. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
26. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000;57:237-45.
27. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193-208.
28. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122:593-624.
29. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995;52:805-18.
30. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol 1998;392:402-12.
31. Garey LJ, Ong WY, Patel TS, Kanani A, Mortimer AM, Barnes TRE, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 1998;65:446-53.
32. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000;57:65-73.
33. Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995;66:309-19.
34. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990;47:1023-8.
35. Popken GJ, Bunney WE Jr, Potkin SG, Jones EG. Subnucleus-specific loss of neurons in medial thalamus of schizophrenic. Proc Natl Acad Sci U S A 2000;97:9276-80.
36. Burns J, Job D, Bastin ME, Whalley H, Macgillivray T, Johnstone EC, et al. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br J Psychiatry 2003;182:439-43.
37. Lim KO, Helpern JA. Neuropsychiatric applications of DTI - a review. NMR Biomed 2002;15:587-93.
38. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. White-matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003;60:443-56.
39. Engel AK, Konig P, Kreiter AK, Singer W. Interhemispheric synchronization of oscillatory neuronal responses in cat visual cortex. Science 1991;252:1177-9.
40. Singer W, Gray CM. Visual feature integration and the temporal correlation hypothesis. Annu Rev Neurosci 1995;18:555-86.
41. Tallon-Baudry C, Bertrand O. Oscillatory gamma activity in humans and its role in object representation. Trends Cogn Sci 1999;3:151-62.
42. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci 2003;23:7407-11.
43. Vianin P, Posada A, Hugues E, Franck N, Bovet P, Parnas J, et al. Reduced P300 amplitude in a visual recognition task in patients with schizophrenia. Neuroimage 2002;17:911-21.
44. Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 1991;30:1059-62.
45. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998;44:716-25.
46. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000;57:1139-47.
47. Parnas J, Bovet P, Innocenti GM. Schizophrenic trait features, binding, and cortico-cortical connectivity: a neurodevelopmental pathogenetic hypothesis. Neurology, Psychiatry and Brain Research 1996;4:185-96.
48. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
49. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? [editorial]. Br Med J (Clin Res Ed) 1987;295:681-2.
50. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit-based model of schizophrenia [review] [91 refs]. Biol Psychiatry 1999;45:17-25.
51. Raedler TJ, Knable MB, Weinberger DR. Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 2000;8:157-61.
52. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998;43:674-9.
53. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12:3721-8.
54. Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck Amsler U, Cuenod M, et al. Gamma-glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995;65:2652-62.
55. Trabesinger AH, Weber OM, Due CO, Boesiger P. Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering. Magn Reson Med 1999;42:283-9.
56. Tosic M, Bovet P, Deppen P, Gheorghita F, Preisig M, Saraga M, et al. Schizophrenia patients show reduced expression of the glutathione-related genes. Soc Neurosci Abstr 2004:909.1.
57. Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP. Initial characterization of the glutamate-cysteine ligase modifier subunit GCLM(-/-) knockout mouse. J Biol Chem 2002;277:49446-52.
58. Do KQ, Bovet P, Cabungcal JH, Castagne V, Gheorghita F, Hornung JP, et al. Glutathione deficit in schizophrenia: a new vulnerability factor for misconnectivity? Schizophrenia Res 2004;67:118.
59. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-60.
60. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000;267:4904-11.
61. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001;30:1191-212.
62. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994;12:1031-40.
63. Zangerle L, Cuenod M, Winterhalter KH, Do KQ. Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices. J Neurochem 1992;59:181-9.
64. Janaky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, et al. Glutathione and signal transduction in the mammalian CNS. J Neurochem 1999;73:889-902.
65. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
66. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 1993;33:513-9.
67. Baldeweg T, Williams JD, Gruzelier JH. Differential changes in frontal and sub-temporal components of mismatch negativity. Int J Psychophysiol 1999;33:143-8.
68. Sullivan JM, Traynelis SF, Chen HS, Escobar W, Heinemann SF, Lipton SA. Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor. Neuron 1994;13:929-36.
69. Colwell CS, Levine MS. Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms. J Neurosci 1995;15:1704-13.
70. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 2000;20:4011-20.
71. Wang J, O'Donnell P. D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 2001;11:452-62.
72. Mukherjee SP, Lynn WS. Role of cellular redox state and glutathione in adenylate cyclase activity in rat adipocytes. Biochim Biophys Acta 1979;568:224-33.
73. Sommer D, Fakata KL, Swanson SA, Stemmer PM. Modulation of the phosphatase activity of calcineurin by oxidants and antioxidants in vitro. Eur J Biochem 2000;267:2312-22.
74. Rabinovic AD, Lewis DA, Hastings TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 2000;101:67-76.
75. Hoyt KR, Reynolds IJ, Hastings TG. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 1997;143:269-81.
76. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996;19:1-17.
77. Yao JK, Reddy RD, van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999;45:1512-5.
78. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998;43:674-9.
79. Liu G. Local structural balance and functional interaction of excitatory and inhibitory synapses in hippocampal dendrites. Nat Neurosci 2004;7:373-9.
80. Castagne V, Cuenod M, Do KQ. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience 2004;123:821-34.
81. Castagne V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 2004;15:93-105.
82. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 2003;62:213-24.
83. Steullet P, Cuenod M, Do KQ. Effect of glutathione deficit on neurotransmission and synaptic plasticity in rat hippocampus: relevance for schizophrenia. Schizophr Res 2003;60:261.
84. Cabungcal JH, Castagne V, Hornung JP, Cuenod M, Do KQ, Schenk F. Visual and olfactory place learning deficit in rats with low glutathione during development: a behaviour model with relevance to schizophrenia. Acta Neurobiologiae Experimentalis 2003;63:31.
85. Heales SJ, Davies SE, Bates TE, Clark JB. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 1995;20:31-8.
86. Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000;22:125-32.
87. Rougemont M, Do KQ, Castagne V. A new model of glutathione deficit during development: effect of glutathione deficit on lipid peroxidation in the rat brain. J Neurosci Res 2003;70:774-83.
88. Do KQ, Bovet P, Cabungcal JH, Castagne V, Gheorghita F, Hornung JP, et al. Glutathione deficit in schizophrenia: a vulnerability factor for disconnectivity? Soc Neurosci Abstr 2004:111.13.
89. Beasley CL, Cotter DR, Everall IP. Density and distribution of white-matter neurons in schizophrenia, bipolar disorder and major depressive disorder: no evidence for abnormalities of neuronal migration. Mol Psychiatry 2002;7:564-70.
90. Hashimoto T, Volk DW, Eggan SM, Mimics K, Pierri JN, Sun Z, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003;23:6315-26.
91. Kume-Kick J, Ferris DC, Russo-Menna I, Rice ME. Enhanced oxidative stress in female rat brain after gonadectomy. Brain Res 1996;738:8-14.
92. Kume-Kick J, Rice ME. Estrogen-dependent modulation of rat brain ascorbate levels and ischemia-induced ascorbate loss. Brain Res 1998;803:105-13.
93. Yolken RH, Karlsson H, Yee F, Johnston-Wilson NL, Torrey EF. Endogenous retroviruses and schizophrenia. Brain Res Brain Res Rev 2000;31:193-9.
94. Nucci C, Palamara AT, Ciriolo MR, Nencioni L, Savini P, D'Agostini C, et al. Imbalance in corneal redox state during herpes simplex virus 1-induced keratitis in rabbits. Effectiveness of exogenous glutathione supply. Exp Eye Res 2000;70:215-20.
95. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989;2:1294-8.
96. Eck HP, Gmunder H, Hartmann M, Petzoldt D, Daniel V, Droge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler 1989;370:101-8.
97. Choi J, Liu RM, Kundu RK, Sangiorgi F, Wu W, Maxson R, et al. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem 2000;275:3693-8.
98. Kharb S. Low whole blood glutathione levels in pregnancies complicated by preeclampsia and diabetes. Clin Chim Acta 2000;294:179-83.
99. Chen G, Wilson R, Cumming G, Walker JJ, Smith WE, McKillop JH. Intracellular and extracellular antioxidant buffering levels in erythrocytes from pregnancy-induced hypertension. J Hum Hypertens 1994;8:37-42.
100. Giblin FJ. Glutathione: a vital lens antioxidant. J Ocul Pharmacol Ther 2000;16:121-35.
101. McCarty CA, Wood CA, Fu CL, Livingston PM, Mackersey S, Stanislavsky Y, et al. Schizophrenia, psychotropic medication, and cataract. Ophthalmology 1999;106:683-7.
102. Davies G, Welham J, Chant D, Torrey EF, Mcgrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull 2003;29:587-93.
103. Harada S, Tachikawa H, Kawanishi Y. Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochem Biophys Res Commun 2001;281:267-71.